Bio-Techne Opened New Manufacturing Hub in Bristol
The 10,000-square-foot facility expands the firm's capacity for producing cell therapy materials for clinical and commercial use.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust that increased private investment in manufacturing will lower costs for advanced medical therapies?
Bio-Techne has officially opened a new GMP-grade small-molecule manufacturing facility in Bristol. The site is currently operational and provides additional production capacity for cell therapy developers.
Why it matters
The expansion addresses the critical need for consistency and scalability in the cell therapy manufacturing supply chain. It integrates into the company's broader network, which includes existing production capabilities in Minnesota.
The Bristol site houses five ISO-8 cleanrooms and two ISO-7 cleanrooms to maintain stringent manufacturing environments. This infrastructure supports production workflows ranging from early-stage development to full commercial manufacturing.
The players
Bio-Techne
A life sciences company that develops and manufactures reagents, instruments, and services for biomedical research and clinical diagnostics.
The details
The facility utilizes controlled-environment cleanrooms classified by ISO standards to minimize particulate contamination during the production of small molecules. ISO-8 and ISO-7 designations refer to the maximum allowable concentration of airborne particles per cubic meter, ensuring the high-purity conditions necessary for materials used in medical cell therapies. This setup allows the firm to scale production processes while maintaining regulatory compliance for clinical-grade outputs.
Timeline
October 13, 2026: The facility opening was officially announced.
The Tech Race
This Bristol facility expands the company's manufacturing footprint, which currently relies on established centers in Minneapolis and St. Paul. The new site strengthens their position in the competitive market for scalable cell therapy production infrastructure.
Cell therapy developers working with the company can now utilize the Bristol site for scaled-up production of clinical materials. The facility is currently operational, allowing immediate integration into existing manufacturing workflows.
The takeaway
This opening underscores a shift toward regionalized, scalable manufacturing for advanced therapies. Watch for future disclosures on the specific therapeutic targets being produced at this site as they move through clinical trials.
Further reading
Learn more about the latest infrastructure developments in the Biotech sector.
Live Poll
Do you trust that increased private investment in manufacturing will lower costs for advanced medical therapies?
